Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes?

被引:12
|
作者
Semenkovich, Tara R. [1 ]
Samson, Pamela P. [2 ]
Hudson, Jessica L. [3 ]
Subramanian, Melanie
Meyers, Bryan F.
Kozower, Benjamin D. [1 ]
Kreisel, Daniel [1 ]
Patterson, G. Alexander [1 ]
Robinson, Clifford G. [2 ]
Bradley, Jeffrey D. [2 ]
Puri, Varun [1 ]
机构
[1] Washington Univ, Div Cardiothorac Surg, Dept Surg, St Louis, MO 63110 USA
[2] Washington Univ, Dept Radiat Oncol, St Louis, MO 63110 USA
[3] Washington Univ, Dept Cardiothorac Surg, 660 S Euclid Ave,Campus Box 8234, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
PHASE-III TRIAL; RANDOMIZED-TRIAL; CHEMORADIOTHERAPY; SURGERY; CHEMOTHERAPY; RADIOTHERAPY;
D O I
10.1016/j.athoracsur.2018.09.064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Wide variation is seen in the dosage of preoperative induction radiation therapy for esophageal cancer. We investigated associations between outcomes after esophagectomy and dosage of induction radiation therapy. Methods. Patients undergoing induction radiation therapy (30 to 70 Gy), followed by esophagectomy, were identified from the National Cancer Database and classified as low (<40 Gy), standard (40 to 50.4 Gy), and high dose (>50.4 Gy). Perioperative outcomes and overall survival were compared. Subgroup analysis compared two common dosages: 45 Gy and 50.4 Gy. Results. From 2004 to 2014, 10,738 patients (84.7%) received standard-dose radiation, increasing from 69.7% in 2004 to 93.6% in 2014 (p < 0.001), 1,329 (10.5%) received low-dose radiation, and 608 (4.8%) received high-dose radiation. Higher rates of pathologic complete response (pCR; low: 11.7%, standard: 16.2%, high: 21.0%; p < 0.001) and downstaging (low: 52.0%, standard: 56.4%, high: 63.1%, p = 0.001) were observed as the dosage increased. On multivariable analysis, compared with standard-dose, high-dose radiation was associated with higher 30-day mortality (odds ratio [OR], 2.11; p < 0.001) without a higher likelihood of downstaging or pCR. Low-dose radiation was associated with lower likelihood of downstaging (OR, 0.85; p = 0.04) and pCR (OR, 0.67; p < 0.001) without lowering the risk of 30-day mortality. The dose of 50.4 Gy was associated with higher likelihood of pCR (OR, 1.12; p = 0.04), without affecting 30-day mortality, compared with 45 Gy. Conclusions. High-dose induction radiation (>50.4 Gy) is associated with increased perioperative death after esophagectomy, without a significant improvement in tumor response. Low-dose radiation (<30 Gy) is associated with worse tumor response without a lower risk of perioperative death. Within standard dosages, 50.4 Gy is associated with higher likelihood of pCR without adversely affecting perioperative mortality compared with 45 Gy. (C) 2019 by The Society of Thoracic Surgeons
引用
收藏
页码:903 / 911
页数:9
相关论文
共 50 条
  • [1] Outcomes with Esophageal Cancer Radiation Therapy
    Zhang, Zhen
    Chen, Yuan
    Chen, Yanzhi
    Jeter, Melenda
    Hofstetter, Wayne L.
    Ajani, Jaffir
    Swisher, Stephen G.
    Chang, Joe Y.
    Allen, Pamela K.
    Cox, James D.
    Komaki, Ritsuko
    Liao, Zhongxing X.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (07) : 880 - 888
  • [2] Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base
    Haque, Waqar
    Verma, Vivek
    Butler, E. Brian
    Teh, Bin S.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 80 - +
  • [3] Induction Therapy for Esophageal Cancer
    Paul, Subroto
    Altorki, Nasser
    THORACIC SURGERY CLINICS, 2013, 23 (04) : 499 - +
  • [4] The Role of Induction Therapy for Esophageal Cancer
    Berry, Mark F.
    THORACIC SURGERY CLINICS, 2016, 26 (03) : 295 - +
  • [5] Improved Outcomes in the Management of Esophageal Cancer with the Addition of Surgical Resection to Chemoradiation Therapy
    McKenzie, Shaun
    Mailey, Brian
    Artinyan, Avo
    Metchikian, Michelle
    Shibata, Stephen
    Kernstine, Kemp
    Kim, Joseph
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (02) : 551 - 558
  • [6] Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity
    Ristau, J.
    Thiel, M.
    Katayama, S.
    Schlampp, I.
    Lang, K.
    Haefner, M. F.
    Herfarth, K.
    Debus, J.
    Koerber, S. A.
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [7] Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy
    Koeter, Marijn
    van der Sangen, Maurice J. C.
    Hurkmans, Coen W.
    Luyer, Misha D. P.
    Rutten, Harm J. T.
    Nieuwenhuijzen, Grard A. P.
    RADIATION ONCOLOGY, 2015, 10
  • [8] Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer
    Venkat, P. S.
    Shridhar, R.
    Naghavi, A. O.
    Hoffe, S. E.
    Almhanna, K.
    Pimiento, J. M.
    Fontaine, J-P.
    Abuodeh, Y.
    Meredith, K. L.
    Frakes, J. M.
    DISEASES OF THE ESOPHAGUS, 2017, 30 (07)
  • [9] Neoadjuvant radiation therapy for esophageal cancer: is a higher dose better?
    Haque, Waqar
    Butler, E. Brian
    Teh, Bin S.
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5631 - 5634
  • [10] Combined modality therapy for patients with esophageal squamous cell carcinoma: Radiation dose and survival analyses
    Shueng, Pei-Wei
    Huang, Chun-Chieh
    Liu, Yu-Ming
    Wu, Yuan-Hong
    Huang, Pin-, I
    Yen, Sang-Hue
    Lin, Kuan-Heng
    Hsu, Chen-Xiong
    THORACIC CANCER, 2023, 14 (02) : 143 - 148